European Commission approves lecanemab for treatment of early Alzheimer’s disease
European Commission approves lecanemab for treatment of early Alzheimer’s disease In a landmark decision, the European Commission has granted EU-wide authorisation for lecanemab, the first medicine to treat mild cognitive […]
AI-Mind Partners Present at Prestigious Alzheimer’s and Parkinson’s Conference in Vienna
AI-Mind Partners Present at Prestigious Alzheimer’s and Parkinson’s Conference in Vienna Partners from the AI-Mind project are proud to present new research findings this week at the International Conference on […]
AI-Mind Share: A Knowledge Hub for Raising Awareness and Sharing Dementia Research
AI-Mind Share: A Knowledge Hub for Raising Awareness and Sharing Dementia Research To mark Brain Awareness Week 2025, a global campaign to increase public awareness of the progress and benefits […]
Special Supplement on the 34th Alzheimer Europe Conference Now Available
Special Supplement on the 34th Alzheimer Europe Conference Now Available: AI-Mind’s Key Contributions and Insights The 34th Alzheimer Europe Conference (34AEC) took place from 8 to 10 October 2024 in […]
AI-Mind featured at LETHE webinar on AI in dementia research
AI-Mind featured at LETHE webinar on artificial intelligence in dementia research On January 17, AI-Mind was showcased during the third event of the LETHE webinar series, titled “Beyond the hype: […]
New publication from AI-Mind on Framework for Evaluating AI-Based Health Technologies
New publication from AI-Mind on Framework for Evaluating AI-Based Health Technologies The AI-Mind project is excited to announce the publication of “Health Technology Assessment Framework for Artificial Intelligence-Based Technologies” by […]
Positive EMA decision on lecanemab highlights importance of AI-Mind’s work
Positive European Medicines Agency decision on lecanemab highlights importance of AI-Mind’s work On 14 November 2024, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended […]
Reporting from the AI-Mind 9th General Assembly
The AI-Mind 9th General Assembly Gathers Experts in Madrid On October 28-29, 2023, AI-Mind partners from The Complutense University of Madrid (UCM) hosted the 9th General Assembly in Madrid, Spain, welcoming […]
AI-Mind Featured on Brain Talks Podcast
Pictures by Brain Innovation Days AI-Mind Featured on Brain Talks Podcast On 28 October 2024, the European Brain Council (EBC) released a new episode of Brain Talks, the podcast produced […]
AI-Mind presents results at Alzheimer Europe conference in Geneva
AI-Mind presents results at Alzheimer Europe conference in Geneva The 34th Alzheimer Europe Conference (#34AEC) took place from 8-10 October in Geneva (Switzerland) bringing together over 950 delegates from 42 […]
AI-Mind consortium meets for 9th General Assembly
The AI-Mind consortium meets for 9th General Assembly The AI-Mind consortium will host its 9th General Assembly (GA9) at the Universidad Complutense de Madrid (UCM) from October 28-29, 2024. The […]
AI-Mind joins Strategic Workshop on Multimodal Health Data Integration
AI-Mind Joined Strategic Workshop on Multimodal Health Data Integration On 24 September, AI-Mind participated in a Strategic Workshop on the challenges of multimodal health data integration, alongside fellow EU-funded projects […]
AI-Mind Consortium to present Results at Alzheimer Europe
AI-MIND Consortium to present results at Alzheimer europe The AI-Mind Consortium is set to make a significant contribution to this year’s Alzheimer Europe Conference taking place in Geneva, Switzerland from […]
World Alzheimer’s Month: Spotlight on Mild Cognitive Impairment and the Role of AI-Mind
World Alzheimer’s Month: Spotlight on Mild Cognitive Impairment and the Role of AI-Mind September is World Alzheimer’s Month, a global campaign raising awareness about dementia and related cognitive disorders. This […]
Negative Opinion on Lecanemab for Early Alzheimer’s Disease
Negative Opinion on Eisai’s Lecanemab for Early Alzheimer’s Disease An application for the marketing authorization of lecanemab, a promising treatment for early-stage Alzheimer’s disease, has faced a setback. The European […]
AI-Mind’s Study Newsletter is Now Available in Five Languages
AI-Mind’s Third Study Newsletter is Now Available in Five Languages We are excited to announce that the third issue of the AI-Mind project study newsletter is now available in five […]
AI-Mind Wins at the AIIC-Awards During the XXIV AIIC National Conference
AI-Mind Wins at the AIIC-Awards During the XXIV AIIC National Conference The third edition of the AIIC-Awards was held during the XXIV AIIC National Conference in Rome, Italy, from 15 […]
New publication on dementia prognostic testing and the effects on quality of life
New publication on dementia prognostic testing and the effects on quality of life The number of people affected by mild cognitive impairment (MCI) continues to rise, leading to a growing […]
European Parliament approved the Artificial Intelligence Act
European Parliament approved the Artificial Intelligence Act Last week, on Wednesday 13th March, the European Parliament ushered in a new era of artificial intelligence (AI) regulation by approving the Artificial […]
Takeaways from AI-Mind’s 8th General Assembly
Takeaways from AI-Mind’s 8th General Assembly The AI-Mind Project consortium gathered for its 8th General Assembly meeting hosted by partners from The Radboud University Medical Center (RUMC) and Oslo University Hospital (OUS) in […]